Benzinga | Oct 19, 2021 06:16AM EDT

SVB Leerink Initiates Coverage On CRISPR Therapeutics with Outperform Rating, Announces Price Target of $126

SVB Leerink analyst Rick Bienkowski initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform rating and announces Price Target of $126.